Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma.

Zinnhardt B, Müther M, Roll W, Backhaus P, Jeibmann A, Foray C, Barca C, Döring C, Tavitian B, Dollé F, Weckesser M, Winkeler A, Hermann S, Wagner S, Wiendl H, Stummer W, Jacobs AH, Schäfers M, Grauer OM.

Neuro Oncol. 2020 Feb 12. pii: noaa023. doi: 10.1093/neuonc/noaa023. [Epub ahead of print]

PMID:
32047908
2.

Multimodal Molecular Imaging of the Tumour Microenvironment.

Foray C, Barca C, Backhaus P, Schelhaas S, Winkeler A, Viel T, Schäfers M, Grauer O, Jacobs AH, Zinnhardt B.

Adv Exp Med Biol. 2020;1225:71-87. doi: 10.1007/978-3-030-35727-6_5. Review.

PMID:
32030648
3.

Re-irradiation for recurrent glioblastoma multiforme: a critical comparison of different concepts.

Baehr A, Trog D, Oertel M, Welsch S, Kröger K, Grauer O, Haverkamp U, Eich HT.

Strahlenther Onkol. 2020 Feb 3. doi: 10.1007/s00066-020-01585-0. [Epub ahead of print]

PMID:
32016497
4.

Combination of ALA-induced fluorescence-guided resection and intraoperative open photodynamic therapy for recurrent glioblastoma: case series on a promising dual strategy for local tumor control.

Schipmann S, Müther M, Stögbauer L, Zimmer S, Brokinkel B, Holling M, Grauer O, Suero Molina E, Warneke N, Stummer W.

J Neurosurg. 2020 Jan 24:1-11. doi: 10.3171/2019.11.JNS192443. [Epub ahead of print]

PMID:
31978877
5.

Initial experience with [18F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system.

Backhaus P, Roll W, Beuker C, Zinnhardt B, Seifert R, Wenning C, Eisenblätter M, Thomas C, Schmidt-Pogoda A, Strunk D, Wagner S, Faust A, Tüttelmann F, Röpke A, Jacobs AH, Stummer W, Wiendl H, Meuth SG, Schäfers M, Grauer O, Minnerup J.

Eur J Nucl Med Mol Imaging. 2020 Jan 20. doi: 10.1007/s00259-019-04662-4. [Epub ahead of print]

PMID:
31960097
6.

An enigmatic case of cortical anopsia: Antemortem diagnosis of a 14-3-3 negative Heidenhain-variant MM1-sCJD.

Obergassel J, Lohmann L, Meuth SG, Wiendl H, Grauer O, Nelke C.

Prion. 2020 Dec;14(1):24-28. doi: 10.1080/19336896.2019.1706703.

7.

Interdisciplinary Decision Making in Hemorrhagic Stroke Based on CT Imaging-Differences Between Neurologists and Neurosurgeons Regarding Estimation of Patients' Symptoms, Glasgow Coma Scale, and National Institutes of Health Stroke Scale.

Wagner A, Schebesch KM, Isenmann S, Steinbrecher A, Kapapa T, Zeman F, Baldaranov D, Grauer O, Backhaus R, Linker RA, Schlachetzki F.

Front Neurol. 2019 Sep 26;10:997. doi: 10.3389/fneur.2019.00997. eCollection 2019.

8.

Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?

Pawlitzki M, Schneider-Hohendorf T, Rolfes L, Meuth SG, Wiendl H, Schwab N, Grauer OM.

Neurol Neuroimmunol Neuroinflamm. 2019 Oct 9;6(6):e627. doi: 10.1212/NXI.0000000000000627. Print 2019 Nov. No abstract available.

9.

Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.

Di Tacchio M, Macas J, Weissenberger J, Sommer K, Bähr O, Steinbach JP, Senft C, Seifert V, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Scheel AH, Büttner R, Grauer OM, Schittenhelm J, Tabatabai G, Harter PN, Günther S, Devraj K, Plate KH, Reiss Y.

Cancer Immunol Res. 2019 Dec;7(12):1910-1927. doi: 10.1158/2326-6066.CIR-18-0865. Epub 2019 Oct 9.

PMID:
31597643
10.

Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis.

Herich S, Schneider-Hohendorf T, Rohlmann A, Khaleghi Ghadiri M, Schulte-Mecklenbeck A, Zondler L, Janoschka C, Ostkamp P, Richter J, Breuer J, Dimitrov S, Rammensee HG, Grauer OM, Klotz L, Gross CC, Stummer W, Missler M, Zarbock A, Vestweber D, Wiendl H, Schwab N.

Brain. 2019 Nov 1;142(11):3411-3427. doi: 10.1093/brain/awz301.

PMID:
31563951
11.

Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.

Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N.

Lancet Oncol. 2019 Oct;20(10):1444-1453. doi: 10.1016/S1470-2045(19)30502-9. Epub 2019 Sep 2.

PMID:
31488360
12.

Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients.

Kristin Schmitz A, Sorg RV, Stoffels G, Grauer OM, Galldiks N, Steiger HJ, Kamp MA, Langen KJ, Sabel M, Rapp M.

Br J Neurosurg. 2019 Aug 13:1-7. doi: 10.1080/02688697.2019.1639615. [Epub ahead of print]

PMID:
31407920
13.

Brain invasion in meningiomas: does surgical sampling impact specimen characteristics and histology?

Timme M, Thomas C, Spille DC, Stummer W, Ebel H, Ewelt C, Hans FJ, Schick U, Puchner M, Wildförster U, Bruns B, Trost HA, Holling M, Grauer O, Hess K, Brokinkel B.

Neurosurg Rev. 2019 Jun 3. doi: 10.1007/s10143-019-01125-0. [Epub ahead of print]

PMID:
31161444
14.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.

Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.

PMID:
30782343
15.

Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients.

Grauer O, Jaber M, Hess K, Weckesser M, Schwindt W, Maring S, Wölfer J, Stummer W.

J Neurooncol. 2019 Jan;141(1):83-94. doi: 10.1007/s11060-018-03005-x. Epub 2018 Dec 1.

16.

Is Visible Aminolevulinic Acid-Induced Fluorescence an Independent Biomarker for Prognosis in Histologically Confirmed (World Health Organization 2016) Low-Grade Gliomas?

Jaber M, Ewelt C, Wölfer J, Brokinkel B, Thomas C, Hasselblatt M, Grauer O, Stummer W.

Neurosurgery. 2019 Jun 1;84(6):1214-1224. doi: 10.1093/neuros/nyy365.

17.

The evolution of cranial meningioma surgery-a single-center 25-year experience.

Sicking J, Voß KM, Spille DC, Schipmann S, Holling M, Paulus W, Hess K, Steinbicker AU, Stummer W, Grauer O, Wölfer J, Brokinkel B.

Acta Neurochir (Wien). 2018 Sep;160(9):1801-1812. doi: 10.1007/s00701-018-3617-6. Epub 2018 Jul 5.

PMID:
29974236
18.

A Novel PKD1 Mutation Associated With Autosomal Dominant Kidney Disease and Cerebral Cavernous Malformation.

Thomas C, Zühlsdorf A, Hörtnagel K, Mulahasanovic L, Grauer OM, Kümpers P, Wiendl H, Meuth SG.

Front Neurol. 2018 May 25;9:383. doi: 10.3389/fneur.2018.00383. eCollection 2018.

20.

Brain invasion and the risk of seizures in patients with meningioma.

Hess K, Spille DC, Adeli A, Sporns PB, Brokinkel C, Grauer O, Mawrin C, Stummer W, Paulus W, Brokinkel B.

J Neurosurg. 2018 Apr 27;130(3):789-796. doi: 10.3171/2017.11.JNS172265.

PMID:
29701550
21.

Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.

Hasselblatt M, Jaber M, Reuss D, Grauer O, Bibo A, Terwey S, Schick U, Ebel H, Niederstadt T, Stummer W, von Deimling A, Paulus W.

J Neuropathol Exp Neurol. 2018 Jun 1;77(6):422-425. doi: 10.1093/jnen/nly012.

PMID:
29444314
22.

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U.

Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204.

23.

Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.

Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG.

Ther Adv Neurol Disord. 2017 Jan;10(1):51-66. doi: 10.1177/1756285616666741. Epub 2016 Sep 2. Review.

24.

Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.

Lutz M, Schulze AB, Rebber E, Wiebe S, Zoubi T, Grauer OM, Keßler T, Kerkhoff A, Lenz G, Berdel WE.

Cancer Res Treat. 2017 Apr;49(2):548-552. doi: 10.4143/crt.2016.110. Epub 2016 Jul 12.

25.

CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.

Dubinski D, Wölfer J, Hasselblatt M, Schneider-Hohendorf T, Bogdahn U, Stummer W, Wiendl H, Grauer OM.

Neuro Oncol. 2016 Jun;18(6):807-18. doi: 10.1093/neuonc/nov280. Epub 2015 Nov 17.

26.

Ibuprofen and Diclofenac Restrict Migration and Proliferation of Human Glioma Cells by Distinct Molecular Mechanisms.

Leidgens V, Seliger C, Jachnik B, Welz T, Leukel P, Vollmann-Zwerenz A, Bogdahn U, Kreutz M, Grauer OM, Hau P.

PLoS One. 2015 Oct 20;10(10):e0140613. doi: 10.1371/journal.pone.0140613. eCollection 2015.

27.

Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid.

Grauer OM, Reichelt D, Grüneberg U, Lohmann H, Schneider-Hohendorf T, Schulte-Mecklenbeck A, Gross CC, Meuth SG, Wiendl H, Husstedt IW.

Ann Clin Transl Neurol. 2015 Sep;2(9):906-19. doi: 10.1002/acn3.227. Epub 2015 Aug 18.

28.

The role of ion channels in malignant brain tumors.

Simon OJ, Müntefering T, Grauer OM, Meuth SG.

J Neurooncol. 2015 Nov;125(2):225-35. doi: 10.1007/s11060-015-1896-9. Epub 2015 Sep 3. Review.

PMID:
26334315
29.

Glioma tissue obtained by modern ultrasonic aspiration with a simple sterile suction trap for primary cell culture and pathological evaluation.

Schroeteler J, Reeker R, Suero Molina E, Brokinkel B, Holling M, Grauer OM, Senner V, Stummer W, Ewelt C.

Eur Surg Res. 2014;53(1-4):37-42. doi: 10.1159/000364943. Epub 2014 Jul 18.

PMID:
25059972
30.

Benefits of contrast-enhanced SWI in patients with glioblastoma multiforme.

Fahrendorf D, Schwindt W, Wölfer J, Jeibmann A, Kooijman H, Kugel H, Grauer O, Heindel W, Hesselmann V, Bink A.

Eur Radiol. 2013 Oct;23(10):2868-79. doi: 10.1007/s00330-013-2895-x. Epub 2013 Aug 1.

PMID:
23903995
31.

New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells.

Gottfried E, Lang SA, Renner K, Bosserhoff A, Gronwald W, Rehli M, Einhell S, Gedig I, Singer K, Seilbeck A, Mackensen A, Grauer O, Hau P, Dettmer K, Andreesen R, Oefner PJ, Kreutz M.

PLoS One. 2013 Jul 9;8(7):e66987. doi: 10.1371/journal.pone.0066987. Print 2013.

32.

Muscle cramps and neuropathies in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease.

Kraus PD, Wolff D, Grauer O, Angstwurm K, Jarius S, Wandinger KP, Holler E, Schulte-Mattler W, Kleiter I.

PLoS One. 2012;7(9):e44922. doi: 10.1371/journal.pone.0044922. Epub 2012 Sep 17.

33.

Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model.

Chirasani SR, Leukel P, Gottfried E, Hochrein J, Stadler K, Neumann B, Oefner PJ, Gronwald W, Bogdahn U, Hau P, Kreutz M, Grauer OM.

Int J Cancer. 2013 Feb 15;132(4):843-53. doi: 10.1002/ijc.27712. Epub 2012 Jul 21.

34.

CD4(+) T cells predominate in cerebrospinal fluid and leptomeningeal and parenchymal infiltrates in cerebral amyloid β-related angiitis.

Melzer N, Harder A, Gross CC, Wölfer J, Stummer W, Niederstadt T, Meuth SG, Marziniak M, Grauer OM, Wiendl H.

Arch Neurol. 2012 Jun;69(6):773-7. doi: 10.1001/archneurol.2011.2441.

PMID:
22351850
35.

Rapidly progressive B-cell dominated inflammatory neuropathy and littoral cell angioma of the spleen associated with plasmablastic B-cell lymphoma.

Melzer N, Barth PJ, Müller KM, Foss HD, Krug U, Schilling M, Marziniak M, Grauer OM, Wiendl H.

Leuk Lymphoma. 2012 Jun;53(6):1242-4. doi: 10.3109/10428194.2011.640677. Epub 2012 Jan 3. No abstract available.

PMID:
22098375
36.

Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).

Grauer O, Pascher C, Hartmann C, Zeman F, Weller M, Proescholdt M, Brawanski A, Pietsch T, Wick W, Bogdahn U, Hau P.

J Neurooncol. 2011 Sep;104(3):801-9. doi: 10.1007/s11060-011-0548-y. Epub 2011 Mar 4. Erratum in: J Neurooncol. 2011 Dec;105(3):671.

PMID:
21373969
37.

Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease.

Grauer O, Wolff D, Bertz H, Greinix H, Kühl JS, Lawitschka A, Lee SJ, Pavletic SZ, Holler E, Kleiter I.

Brain. 2010 Oct;133(10):2852-65. doi: 10.1093/brain/awq245. Epub 2010 Sep 15. Review.

PMID:
20846944
38.

Immunotherapy of diffuse gliomas: biological background, current status and future developments.

Grauer OM, Wesseling P, Adema GJ.

Brain Pathol. 2009 Oct;19(4):674-93. doi: 10.1111/j.1750-3639.2009.00315.x. Review.

PMID:
19744040
39.

RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.

Beier CP, Schmid C, Gorlia T, Kleinletzenberger C, Beier D, Grauer O, Steinbrecher A, Hirschmann B, Brawanski A, Dietmaier C, Jauch-Worley T, Kölbl O, Pietsch T, Proescholdt M, Rümmele P, Muigg A, Stockhammer G, Hegi M, Bogdahn U, Hau P.

BMC Cancer. 2009 Sep 2;9:308. doi: 10.1186/1471-2407-9-308.

40.

Recurrent cardiac arrest caused by lateral medulla oblongata infarction.

von Heinemann P, Grauer O, Schuierer G, Ritzka M, Bogdahn U, Kaiser B, Schlachetzki F.

BMJ Case Rep. 2009;2009. pii: bcr02.2009.1625. doi: 10.1136/bcr.02.2009.1625. Epub 2009 Oct 12.

41.

Bilateral vertebral artery occlusion with retrograde basilary flow in three cases of giant cell arteritis.

Boettinger M, Sebastian S, Gamulescu MA, Grauer O, Ritzka M, Schuierer G, Bogdahn U, Steinbrecher A, Schlachetzki F.

BMJ Case Rep. 2009;2009. pii: bcr07.2008.0488. doi: 10.1136/bcr.07.2008.0488. Epub 2009 Feb 26. Erratum in: BMJ Case Rep. 2009;2009:bcr0720080488corr1. Boettinger, Markus Robert [corrected to Boettinger,Markus]; Sebastian, Schreglmann Robert [corrected to Sebastian, Schreglmann]; Gamulescu, Maria-Andreea Robert [corrected to Gamulescu, Maria-Andreea]; Schuierer, Gerhard Robert [corrected to Schuierer, Ger.

42.

Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.

Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, Grotenhuis JA, Hoogerbrugge PM, de Vries IJ, Adema GJ.

Neuro Oncol. 2009 Aug;11(4):394-402. doi: 10.1215/15228517-2008-104. Epub 2008 Nov 21.

43.

TLR ligands in the local treatment of established intracerebral murine gliomas.

Grauer OM, Molling JW, Bennink E, Toonen LW, Sutmuller RP, Nierkens S, Adema GJ.

J Immunol. 2008 Nov 15;181(10):6720-9.

44.

In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy.

Nierkens S, den Brok MH, Sutmuller RP, Grauer OM, Bennink E, Morgan ME, Figdor CG, Ruers TJ, Adema GJ.

Cancer Res. 2008 Jul 1;68(13):5390-6. doi: 10.1158/0008-5472.CAN-07-6023. Erratum in: Cancer Res. 2008 Aug 15;68(16):6859.

45.

Selective cancer-germline gene expression in pediatric brain tumors.

Jacobs JF, Grauer OM, Brasseur F, Hoogerbrugge PM, Wesseling P, Gidding CE, van de Rakt MW, Figdor CG, Coulie PG, de Vries IJ, Adema GJ.

J Neurooncol. 2008 Jul;88(3):273-80. doi: 10.1007/s11060-008-9577-6. Epub 2008 Apr 9.

46.

Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.

Grauer OM, Sutmuller RP, van Maren W, Jacobs JF, Bennink E, Toonen LW, Nierkens S, Adema GJ.

Int J Cancer. 2008 Apr 15;122(8):1794-802.

47.

CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo.

Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P, Sutmuller RP, Adema GJ.

Int J Cancer. 2007 Jul 1;121(1):95-105.

48.

Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2.

Grauer O, Pöschl P, Lohmeier A, Adema GJ, Bogdahn U.

J Neurooncol. 2007 Apr;82(2):151-61. Epub 2006 Nov 15.

PMID:
17106649
49.

Toll-like receptors on regulatory T cells: expanding immune regulation.

Sutmuller RP, Morgan ME, Netea MG, Grauer O, Adema GJ.

Trends Immunol. 2006 Aug;27(8):387-93. Epub 2006 Jun 30. Review.

PMID:
16814607
50.

Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy--a phase-II study.

Wismeth C, Hau P, Fabel K, Baumgart U, Hirschmann B, Koch H, Jauch T, Grauer O, Drechsel L, Brawanski A, Bogdahn U, Steinbrecher A.

J Neurooncol. 2004 May;68(1):79-86.

PMID:
15174524

Supplemental Content

Loading ...
Support Center